semaglutide cardiovascular trial SELECT Beyond obesity: Novo's SELECT re-defines

Injection Anxiety or Administration Difficulties Self-injecting weekly is not trivial, and for some patients the psychological barrier is simply too significant to overcome

Bottom Line The 2019-2026 diabetes and obesity peptide pipeline is no longer just "more GLP-1." It is a multi-pathway race across triple agonists, amylin combinations, dual GLP-1/glucagon drugs, and longer-acting metabolic peptide designs

Nutrition varies widely by chef (calories range from 360 to 1,200+), and a weekly subscription is required at $11$14 per meal

Variants in GLP1R, GIPR, FTO, and MC4R genes may provide context for underlying metabolic predispositions, helping providers understand whether an adolescent's weight concerns reflect genetic susceptibility to appetite regulation or energy storage patterns

Horsham warns